Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New tool could spot tough pneumonia early

NCT ID NCT07425561

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study created and tested a risk score called RESPIRE to predict whether a patient's pneumonia is caused by multidrug-resistant bacteria. Researchers looked at data from 300 adults with community-acquired pneumonia in the emergency department. The goal is to help doctors quickly identify high-risk patients, but the score is not yet ready for routine use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give doctors a simple tool to quickly identify pneumonia patients at risk for drug-resistant infections, helping guide early treatment decisions.
What could go wrong
This is an observational study, not a treatment trial. The score needs further testing in other hospitals and may not work as well in different populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

300 people

The number who actually took part.

Started

Jan 2022

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

During the initial retrospective observational phase (2 years), data were collected to establish a retrospective derivation cohort composed of patients with microbiologically confirmed etiological diagnoses of pneumonia. The derivation cohort includes patients who underwent microbiological investigations aimed at identifying the etiological cause of pneumonia within the first 48 hours of presentation to Azienda Ospedaliero Universitaria Careggi. During the second prospective observational phase (2 years), data were collected to establish a prospective cohort of Emergency Department patients, in which the performance of the clinical score derived from the retrospective cohort was evaluated in a purely observational manner.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All patients: * aged ≥18 years * who underwent respiratory sample collection within 48 hours of hospital admission and had subsequent positive culture results oleading to a confirmed etiological diagnosis of community-acquired pneumonia (CAP) * Pneumonia was clinically defined by the presence of two or more clinical signs or symptoms (body temperature \<36.0°C or \>38.0°C; respiratory rate \>20 breaths/min; oxygen saturation on room air \<90%; arterial partial pressure of oxygen \<60 mmHg; cough; sputum production; white blood cell count \<4,000/μL or \>10,000/μL; bandemia \>10%), in addition to radiographic evidence of a new parenchymal opacity or cavitation. * Only patients with positive respiratory culture results were included in the analysis. During the prospective phase, only patients whose microbiological samples were collected in the Emergency Department were enrolled. Exclusion Criteria: * informed consent was not provided * age was \<18 years or \>90 years * pregnant * pneumonia occurred after more than 48 hours from hospital admission (hospital-acquired pneumonia).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Community acquired pneumonia (CAP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial pneumonia Community-Acquired Pneumonia Emergencies pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Careggi University Hospital

    Florence, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.